Related content

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia

By Emadi Ashkan   Karp Judith E  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1257-1269

Future Medicine

Access to resources Recommend Favorite

Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies.

By  

Current Pharmaceutical Biotechnology, Vol. 17, Iss. 1, 2016-01 ,pp. : 42-51

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies

By Dulucq Stéphanie   Laverdière Caroline   Sinnett Daniel   Krajinovic Maja  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 699-719

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomic considerations for immunosuppressive therapy

By Yagil Yoram   Yagil Chana  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 309-319

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic considerations of the paraoxonase polymorphisms

By Furlong Clement E   Cole Toby B   Jarvik Gail P   Costa Lucio G  

Pharmacogenomics, Vol. 3, Iss. 3, 2002-05 ,pp. : 341-348

Future Medicine

Access to resources Recommend Favorite